Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

aerosolized liposomal rubitecan

An aerosolized liposomal preparation of rubitecan, a water-insoluble derivative of camptothecin with potential antineoplastic activity. Rubitecan (or 9-nitro-20 (S)-camptothecin) and its active metabolite 9-aminocamptothecin (9-AC) selectively stabilize topoisomerase I-DNA covalent complexes during S-phase, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery. This agent is formulated with dilauroylphosphatidylcholine and nebulized in particle sizes of 1.2-1.6 micrometer mass median aerodynamic diameter.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:aerosolized liposomal 9-nitro-20(S)-camptothecin
aerosolized liposomal 9-nitrocamptothecin
Code name:L9NC
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search